MTHFD2 and cholangiocarcinoma: As reflected by TIMER analysis, MTHFD2 expression was considerably augmented in multiple types of cancers, like BLCA, breast cancer, cholangiocarcinoma, colon adenocarcinoma, and kidney renal clear cell carcinoma (Fig. 1A).